OptimizeRx (NASDAQ:OPRX – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
A number of other analysts also recently issued reports on the stock. Stephens lowered their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 6th. B. Riley Financial reissued a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Lake Street Capital lowered their price target on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Roth Mkm lowered their price target on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Stifel Nicolaus lowered their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.57.
Check Out Our Latest Research Report on OptimizeRx
OptimizeRx Stock Down 2.1%
OptimizeRx (NASDAQ:OPRX – Get Free Report) last released its quarterly earnings data on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. As a group, equities research analysts anticipate that OptimizeRx will post 0.5 EPS for the current year.
OptimizeRx declared that its board has initiated a stock buyback plan on Thursday, March 5th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Hedge Funds Weigh In On OptimizeRx
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hillsdale Investment Management Inc. lifted its holdings in OptimizeRx by 10.9% during the fourth quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after purchasing an additional 2,000 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. AQR Capital Management LLC lifted its holdings in OptimizeRx by 18.4% during the fourth quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock valued at $178,000 after purchasing an additional 2,256 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in OptimizeRx by 12.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after purchasing an additional 2,708 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.
OptimizeRx Company Profile
OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.
The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.
Read More
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
